Faeth Therapeutics (FTH)
Nasdaq Market Closed
Last updated
- Market Cap
- $18,585,883
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- -$133,721,117
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE, MD, 20850
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $18,585,883
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -$133,721,117
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -0.14
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.72
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -137.46
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$24,114,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 134.36%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -89.81%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 14.39
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 14.39
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 10.73
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $52,840
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 13.85
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -170.63M | -4.96M | -4.85M | -5.21M | -7.27M |
| EBITDA | -170.6M | -4.91M | -4.82M | -5.18M | -7.24M |
| Net income | -170.24M | -4.72M | -4.57M | -4.94M | -6.86M |
| Basic EPS | -131.45 | -3.74 | -3.62 | -3.91 | -5.45 |
| Diluted EPS | -131.45 | -3.74 | -3.62 | -3.91 | -5.45 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 205.38M | 22.9M | 27.59M | 31.78M | 38.27M |
| Total liabilities | 14.19M | 4.31M | 4.58M | 4.47M | 6.29M |
| Total equity | -137.29M | 18.59M | 23.01M | 27.31M | 31.99M |
| Cash & equivalents | 152.33M | 8.67M | 10.56M | 12.56M | 9.88M |
| Current assets | 204.23M | 21.51M | 25.79M | 29.57M | 35.68M |
| Current liabilities | 14.19M | 4.25M | 4.44M | 3.87M | 5.23M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -10.73M | -3.86M | -3.59M | -5.91M | -7.09M |
| Investing cash flow | -31.44M | 2.08M | 1.74M | 8.76M | 7.19M |
| Financing cash flow | 185.83M | -111K | -152K | -168K | -214K |
| Change in cash | 143.66M | -1.89M | -2M | 2.68M | -117K |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Faeth Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| edgar index | SCHEDULE 13G — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 3 — Faeth Therapeutics, Inc. | View Filing | |
| form 3 | Form 3 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — STEPHENSON BRIAN C | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| edgar index | S-3ASR — Faeth Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Faeth Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 3 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| form 3 | Form 3 — Ramasastry Saira | View Filing | |
| form 3 | Form 3 — Ramasastry Saira | View Filing | |
| form 3 | Form 3 — Hahn Stephen M. | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Parikh Anand Kiran | View Filing | |
| form 4 | Form 4 — Hahn Stephen M. | View Filing | |
| form 4 | Form 4 — Hahn Stephen M. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | EFFECT — Sensei Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Ramasastry Saira | View Filing | |
| form 4 | Form 4 — Hahn Stephen M. | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | S-3/A — Sensei Biotherapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Donenberg Phillip B. | View Filing | |
| form 4 | Form 4 — Holmen Bob | View Filing | |
| form 4 | Form 4 — Gerry Christopher | View Filing | |
| edgar index | SCHEDULE 13G/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | S-3/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 10-K/A — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| edgar index | 4 — Sensei Biotherapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Peyer James | View Filing | |
| form 4 | Form 4 — Peyer James | View Filing | |
| form 4 | Form 4 — Cambrian BioPharma Inc | View Filing | |
| form 4 | Form 4 — Cambrian BioPharma Inc | View Filing | |
| edgar index | 8-K — Sensei Biotherapeutics, Inc. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free